Trial Profile
WT1-antigen specific TCR-gene transduced T lymphocytes transfer using MS3-WT1-siTCR vector for acute myelogeneous leukaemia and myelodysplastic syndrome
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Jan 2017
Price :
$35
*
At a glance
- Drugs WT1 TCR-transduced T cells-Takara Bio (Primary) ; WT1 peptide vaccine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; First in man
- Sponsors Takara Bio
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 08 Nov 2016 Status changed from active, no longer recruiting to completed.
- 25 Mar 2014 New trial record